New Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
New Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - January 17, 2014 Category: Gastroenterology Authors: Medscape Source Type: podcasts
CAIRO-3 Trial Updates - Dr. Scott Berry
Dr. Scott Berry with an update from ECC 2013 on maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic col...
Author: oncologyeducation
Added: 10/07/2013 (Source: Oncology Tube)
Source: Oncology Tube - October 7, 2013 Category: Cancer & Oncology Source Type: podcasts
ABSTRACT #337: Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
Axel Grothey discusses Abstract #337; Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a ...
Author: imedex
Added: 02/04/2013 (Source: Oncology Tube)
Source: Oncology Tube - February 4, 2013 Category: Cancer & Oncology Source Type: podcasts
